RxDoctor Payments Data

Robyn Faye, MD

Gynecology · Blue Bell, PANPI 1356343297

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Bayer at 30.6% of the total. 2025 is the largest year on record at $2,398, 7.2 times the $333 reported in 2019.

$5,228in general payments, 2019–2025

Across 100 payments — averaging $52.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Scynexis, Inc.$1K
  • Mayne Pharma Commercial LLC$569
  • AbbVie$488
  • Astellas Pharma US Inc$378
  • Millicent US Inc$184
  • plus $885 from 14 others

What the payments were for

  • Consulting fees$1,00019%
  • Speaking & faculty fees$1,60031%
  • Food & beverage$2,58849%
  • Education$401%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,228 in reported general payments places this provider in the 85th percentile of 98 gynecology providers in Pennsylvania.

See all gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$60,893
Medicare patients
443
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet36$21,771
Estradiol238$21,503
PremarinEstrogens, Conjugated34$16,741
Clobetasol Propionate200$9,596
VeozahFezolinetant15$7,815
YuvafemEstradiol28$4,749
Estradiol (Twice Weekly)Estradiol27$3,728
Alendronate Sodium218$3,465
ValacyclovirValacyclovir Hcl41$2,936
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet16$2,377
ProgesteroneProgesterone, Micronized36$2,147
Estradiol (Once Weekly)Estradiol12$1,795
Risedronate Sodium12$886
Betamethasone Dipropionate27$754
Gabapentin31$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPrempro, Premarin$29$38,51270 claims
Astellas Pharma US IncVeozah$378$7,81515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 gynecology providers in Pennsylvania.

Other gynecology in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →